TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24083783

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention focused on general practitioners (GPs) including training, electronic blood pressure measurement device, and recommendation leaflet
Number of subjects: 1832

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention focused on general practitioners (GPs)
Number of subjects: 1832

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1832
Study: 21906708

Group type: EXPERIMENTAL
Intervention: Angiographically plus computed tomographically guided (ACTG)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Angiographically guided
Number of subjects: 71
Study: 18653315

Group type: EXPERIMENTAL
Intervention: Carrot juice (330 mL daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tomato juice (330 mL daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spinach powder (10 g daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low carotenoid period
Number of subjects: 0
Study: 16780548

Group type: EXPERIMENTAL
Intervention: Prophylaxis (valganciclovir 900 mg q.d. for 100 days)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Preemptive therapy (valganciclovir 900 mg b.i.d. for 21 days)
Number of subjects: 98
Study: 14606102

Group type: EXPERIMENTAL
Intervention: Rabeprazole (RAB) 10 mg
Number of subjects: 40
Study: 10960446

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control
Number of subjects: 42
Study: 8877029

Group type: EXPERIMENTAL
Intervention: Loperamide (16 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Loperamide (2 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Loperamide (6 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Loperamide plus naloxone
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Naloxone alone
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Bethanechol
Number of subjects: 6
Study: 1889499

Group type: EXPERIMENTAL
Intervention: Sodium thiophene carboxylate (600 mg per day for 21 days)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 6529891

Group type: EXPERIMENTAL
Intervention: Self blood glucose monitoring by meter
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Self blood glucose monitoring by visually read strips
Number of subjects: 24

Group type: COMPARATOR
Intervention: Urine glucose monitoring
Number of subjects: 24
Study: 3886851

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (Group 1, 62 cases)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo (Group 2, 60 cases)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (Group 3, 25 cases)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo (Group 4, 27 cases)
Number of subjects: 174
Study: 29316931

Group type: EXPERIMENTAL
Intervention: Novel multi-component fortifier and protein supplement derived from donkey milk
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control bovine milk-based multicomponent fortifier and protein supplement
Number of subjects: 0
Study: 27434084

Group type: EXPERIMENTAL
Intervention: β-alanine supplementation (6.4 g·d for 28 days)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: β-alanine supplementation (1.2 g·d during 5 weeks of SIT)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: β-alanine supplementation
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 24447063

Group type: EXPERIMENTAL
Intervention: 1-day health education program
Number of subjects: 738
Study: 23348419

Group type: EXPERIMENTAL
Intervention: Hot objects
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cold objects
Number of subjects: 60
Study: 21206546

Group type: EXPERIMENTAL
Intervention: Ramelteon 8 mg (n = 8)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (n = 13)
Number of subjects: 21
Study: 18818093

Group type: EXPERIMENTAL
Intervention: Partially covered self-expandable metallic stent (SEMS)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Bare self-expandable metallic stent (SEMS)
Number of subjects: 62

Group type: COMPARATOR
Intervention: External biliary drainage tube insertion
Number of subjects: 62
Study: 16005229

Group type: EXPERIMENTAL
Intervention: Antiestrogen therapy for 3 years after primary surgery and radiotherapy
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: p53 positivity
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: High clinical stage and negative estrogen receptor status
Number of subjects: 97
Study: 12929694

Group type: EXPERIMENTAL
Intervention: Root ZX
Number of subjects: 32

Group type: COMPARATOR
Intervention: Endo Analyzer Model 8005
Number of subjects: 32
Study: 10664481

Group type: EXPERIMENTAL
Intervention: Parallel orientation aiming task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perpendicular orientation aiming task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonlinear measures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postural organization for upright standing and aiming
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postural variability
Number of subjects: 0
Study: 8842657

Group type: EXPERIMENTAL
Intervention: Midazolam 0.4 mg kg‐1 i.v. (15 patients)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propofol 1 mg kg‐1 i.v. bolus, followed by continuous infusion (15 patients)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both groups (Midazolam and Propofol) after intubation
Number of subjects: 30
Study: 1496708

Group type: EXPERIMENTAL
Intervention: Young coconut water
Number of subjects: 0
Study: 6130295

Group type: EXPERIMENTAL
Intervention: Red-cell concentrate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Red-cell suspension in SAGM medium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Whole blood
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Red cells
Number of subjects: 0
Study: 31727361

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg combined with rosuvastatin 5 mg (R5 + E10)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg combined with Ezetimibe 10 mg (R10 + E10)
Number of subjects: 408
Study: 28692728

Group type: EXPERIMENTAL
Intervention: BLISS intervention (baby-led approach to complementary feeding)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control group (traditional spoon-feeding)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: BLISS intervention
Number of subjects: 206
Study: 25847819

Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy (3D-CRT)
Number of subjects: 763

Group type: COMPARATOR
Intervention: Intensity-modulated radiation therapy (IMRT)
Number of subjects: 763
Study: 24346989

Group type: EXPERIMENTAL
Intervention: Scaling and root planing plus chlorhexidine oral rinse at baseline and supportive periodontal therapy at 3 and 6 months
Number of subjects: 514

Group type: COMPARATOR
Intervention: No treatment for 6 months
Number of subjects: 514
Study: 21304215

Group type: EXPERIMENTAL
Intervention: Fluvastatin 60 mg (F60)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg combined with ezetimibe 10 mg (F20/E10)
Number of subjects: 2
Study: 19258829

Group type: EXPERIMENTAL
Intervention: Presurgical exercise training
Number of subjects: 9
Study: 16681770

Group type: EXPERIMENTAL
Intervention: Array-based comparative genomic hybridization (array CGH)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: TaqMan polymerase chain reaction
Number of subjects: 60
Study: 14975458

Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg daily
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Aspirin plus nimesulide
Number of subjects: 34

Group type: COMPARATOR
Intervention: Fradafiban (control group)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: All treatments (Aspirin, Nimesulide, Fradafiban)
Number of subjects: 34
Study: 11564023

Group type: EXPERIMENTAL
Intervention: Aquadry Clear Advantage sheath
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Incare sheath
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Sheaths with applicator
Number of subjects: 58
Study: 10345907

Group type: EXPERIMENTAL
Intervention: Nutrition education
Number of subjects: 408

Group type: COMPARATOR
Intervention: Stress management (attention-placebo control)
Number of subjects: 408
Study: 8071301

Group type: EXPERIMENTAL
Intervention: Open treatment with clinician's choice, including continued phenelzine and combination with amitriptyline
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Open treatment with clinician's choice, including a variety of other treatments
Number of subjects: 20
Study: 3377948

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 1 mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 2 mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine
Number of subjects: 44

Group type: COMPARATOR
Intervention: i.v. morphine 30 mg
Number of subjects: 44
Study: 4877736

Group type: EXPERIMENTAL
Intervention: House dust extract in a carbol saline solution
Number of subjects: 96

Group type: COMPARATOR
Intervention: Carbol saline solution only (control)
Number of subjects: 96
Study: 31714106

Group type: EXPERIMENTAL
Intervention: Judgments of friends' drinking status and maximum drinks per day
Number of subjects: 654

Group type: EXPERIMENTAL
Intervention: Frequency of contact with friends
Number of subjects: 654

Group type: EXPERIMENTAL
Intervention: Friends' weekly consumption
Number of subjects: 654
Study: 30737835

Group type: EXPERIMENTAL
Intervention: Docetaxel with prednisone (5 mg twice daily for 3 cycles)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Docetaxel monotherapy
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Docetaxel with prednisone
Number of subjects: 18
Study: 28549331

Group type: EXPERIMENTAL
Intervention: High Chances of Quitting (HCQ)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Average Chances of Quitting (ACQ)
Number of subjects: 103
Study: 25735497

Group type: EXPERIMENTAL
Intervention: Ramosetron 0.6 mg mixed with PCA (RPCA group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Palonosetron 75 μg (P group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ramosetron 0.3 mg (R0.3 group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline (C group)
Number of subjects: 0
Study: 23438090

Group type: EXPERIMENTAL
Intervention: Intervention group (web-assisted tobacco quality improvement intervention)
Number of subjects: 564

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 564

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 564
Study: 21705068

Group type: EXPERIMENTAL
Intervention: Diet intervention (dietary consultation every 3 months with monthly nurse support)
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Diet plus activity intervention (dietary consultation every 3 months with monthly nurse support plus a pedometer-based activity programme)
Number of subjects: 593

Group type: COMPARATOR
Intervention: Usual care (initial dietary consultation and follow‐up every 6 months)
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Diet intervention and diet plus activity
Number of subjects: 593
Study: 19324137

Group type: EXPERIMENTAL
Intervention: General anesthesia plus epidural (GAE)
Number of subjects: 74

Group type: COMPARATOR
Intervention: General anesthesia only (GA)
Number of subjects: 74
Study: 16981967

Group type: EXPERIMENTAL
Intervention: Once-daily urokinase (5000-6000 IU/kg/dose)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Twice-daily urokinase (2500-3000 IU/kg/dose)
Number of subjects: 30
Study: 15194094

Group type: EXPERIMENTAL
Intervention: All-polyethylene (AP) tibial component
Number of subjects: 21

Group type: COMPARATOR
Intervention: Metal-backed (MB) tibial component
Number of subjects: 21
Study: 10775722

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia (2% lidocaine and 100 microg of fentanyl infused through lumbar epidural catheters)
Number of subjects: 108

Group type: COMPARATOR
Intervention: No anesthesia (control group)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 108
Study: 9286186

Group type: EXPERIMENTAL
Intervention: Fluoxetine (80 mg/day)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Phenelzine (60 mg/day)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 8139135

Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant human erythropoietin (rHuEPO) at doses of 3,000 and 6,000 IU, administered once per week for 8 weeks.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intravenous recombinant human erythropoietin (rHuEPO) at doses of 3,000, 6,000, and 9,000 IU, administered once per week for 8 weeks.
Number of subjects: 20
Study: 2949974

Group type: EXPERIMENTAL
Intervention: Ticlopidine (500 mg daily)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 29105279

Group type: EXPERIMENTAL
Intervention: Low-frequency sphenopalatine ganglion stimulation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 16
Study: 27590291

Group type: EXPERIMENTAL
Intervention: Alemtuzumab 12 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: SC IFN‐β‐1a 44 μg
Number of subjects: 0
Study: 24943673

Group type: EXPERIMENTAL
Intervention: Commercial Programme for 12 weeks
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Commercial Programme for 52 weeks
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Brief Intervention
Number of subjects: 1200
Study: 22288770

Group type: EXPERIMENTAL
Intervention: Static magnetic field (SMF) exposure (0-192 mT peak-to-peak magnetic induction and 19 T/m lateral gradient at 3 mm from the magnets) for 5 minutes
Number of subjects: 79

Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 79
Study: 20868461

Group type: EXPERIMENTAL
Intervention: Family‐Focused Treatment‐Health Promoting Intervention (FFT‐HPI)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 46
Study: 20031665

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 635

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 635
Study: 17219034

Group type: EXPERIMENTAL
Intervention: Ropinirole at 15 mg per day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pramipexole at 2.1 mg per day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Patients who experienced 'wearing-off'
Number of subjects: 60

Group type: COMPARATOR
Intervention: Patients who did not experience 'wearing-off'
Number of subjects: 60
Study: 14709221

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) with parameters: wavelength of 830 nm, power of 30 mW, frequency of 30 Hz, energy output of 1.1 J/cm2
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo LLLT
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: LLLT
Number of subjects: 20
Study: 11106918

Group type: EXPERIMENTAL
Intervention: octreotide LAR 20 mg once monthly for three months
Number of subjects: 125
Study: 8842608

Group type: EXPERIMENTAL
Intervention: Hyperglycemia (blood glucose 15.7 +/‐ 0.48 mmol/l)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Euglycemia (blood glucose 5.1 +/‐ 0.04 mmol/l)
Number of subjects: 6
Study: 8197926

Group type: EXPERIMENTAL
Intervention: Various statistical concepts related to trial design and analysis
Number of subjects: 0
Study: 2981045

Group type: EXPERIMENTAL
Intervention: Human growth hormone (hGH) 7 IU subcutaneously daily for 2 months, followed by salmon calcitonin (CT), 100 MRC units every other day for 3 months, repeated twice after a 3 month rest period
Number of subjects: 14

Group type: COMPARATOR
Intervention: Salmon calcitonin (CT) given intermittently in the same time periods and at the same dose as in the coherence treatment group
Number of subjects: 14
Study: 31520149

Group type: EXPERIMENTAL
Intervention: Psycho-educational group therapy module (STEM) with 8 sessions plus 3 sessions on stigma coping and empowerment
Number of subjects: 462

Group type: COMPARATOR
Intervention: Standard psychoeducational group therapy extended to 11 sessions plus 1 booster session
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Psycho-educational group therapy module (STEM)
Number of subjects: 462

Group type: COMPARATOR
Intervention: Standard psychoeducational group therapy
Number of subjects: 462
Study: 29478929

Group type: EXPERIMENTAL
Intervention: Persica (herbal mouthwash)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Ortho-Kin (diluted chlorhexidine mouthwash)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both mouthwashes (Persica and Ortho-Kin)
Number of subjects: 54
Study: 27706464

Group type: EXPERIMENTAL
Intervention: High-flow conditioned oxygen therapy
Number of subjects: 604

Group type: COMPARATOR
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 604
Study: 25915102

Group type: EXPERIMENTAL
Intervention: NIV
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 221

Group type: COMPARATOR
Intervention: Lifestyle modification (control group)
Number of subjects: 221
Study: 24314053

Group type: EXPERIMENTAL
Intervention: Ego-depletion condition
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 130
Study: 21178076

Group type: EXPERIMENTAL
Intervention: DHA supplementation (400 mg daily)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study: 18294405

Group type: EXPERIMENTAL
Intervention: Early part-time sick leave (work time reduced by 40-60%)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Conventional full-day sick leave (work load totally eliminated)
Number of subjects: 600
Study: 16282531

Group type: EXPERIMENTAL
Intervention: Nonparametric inference procedures for Omega in the presence of dependent and independent censoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonparametric inference procedures for Omega in the presence of dependent interval censorship
Number of subjects: 0
Study: 14583235

Group type: EXPERIMENTAL
Intervention: Left hemisphere's hematoma
Number of subjects: 26

Group type: COMPARATOR
Intervention: Right hemisphere's hematoma
Number of subjects: 26
Study: 10890617

Group type: EXPERIMENTAL
Intervention: Ornithine alpha-ketoglutarate
Number of subjects: 47

Group type: COMPARATOR
Intervention: Protil-1 (isonitrogenous control)
Number of subjects: 47
Study: 7602235

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: EPO 150 U/kg
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: EPO 300 U/kg
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: EPO 600 U/kg
Number of subjects: 71
Study: 2403585

Group type: EXPERIMENTAL
Intervention: Amniotomy
Number of subjects: 53

Group type: COMPARATOR
Intervention: No amniotomy
Number of subjects: 53
Study: 580217

Group type: EXPERIMENTAL
Intervention: 1‐(m‐methoxyphenyl)‐2‐(dimethylaminomethyl)‐cyclohexan‐1‐ol (tramadol; Tramal) 100 mg i.m.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30091151

Group type: EXPERIMENTAL
Intervention: Client with current suicidal ideation and a history of attempts
Number of subjects: 86

Group type: COMPARATOR
Intervention: Client without explicitly elevated suicide risk
Number of subjects: 86
Study: 28128852

Group type: EXPERIMENTAL
Intervention: 200 mg GLE + 80 mg PIB (arm A)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 300 mg GLE + 120 mg PIB with 800 mg once-daily RBV (arm B)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 300 mg GLE + 120 mg PIB without RBV (arm C)
Number of subjects: 50
Study: 26050074

Group type: EXPERIMENTAL
Intervention: Immediate-start cueing exercise program
Number of subjects: 21

Group type: COMPARATOR
Intervention: Delayed-start cueing exercise program
Number of subjects: 21
Study: 22093001

Group type: EXPERIMENTAL
Intervention: Fresh-frozen allogeneic (AL) block bone grafts
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Autologous (AT) block bone grafts
Number of subjects: 26
Study: 21733435

Group type: EXPERIMENTAL
Intervention: Augment™ Bone Graft
Number of subjects: 20

Group type: COMPARATOR
Intervention: ABG
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 19955857

Group type: EXPERIMENTAL
Intervention: LAT patients
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: LAT patients without warfarin
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: LAT patients with INR >= 2.0
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: LAT patients undergoing repeat TEE
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: AF patients with persistent LAT
Number of subjects: 226
Study: 16765701

Group type: EXPERIMENTAL
Intervention: Manual small-incision cataract surgery (MSICS)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Phacoemulsification (PE)
Number of subjects: 150
Study: 14706957

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 540) received individualized counseling about modifying fat quality and quantity in diet.
Number of subjects: 1062

Group type: COMPARATOR
Intervention: Control group (n = 522) did not receive the same dietary counseling.
Number of subjects: 1062

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 540)
Number of subjects: 1062

Group type: COMPARATOR
Intervention: Control group (n = 522)
Number of subjects: 1062

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1062
Study: 11715663

Group type: EXPERIMENTAL
Intervention: Essential phospholipids (EPL) administered intravenously, 50 mg every 6 hours for 2 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group without hepatoprotection
Number of subjects: 20
Study: 9383499

Group type: EXPERIMENTAL
Intervention: Granisetron (1 mg tablets/2 mg oral dose)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg tablets/8 mg oral dose)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 8042069

Group type: EXPERIMENTAL
Intervention: Short course treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 100
Study: 3392240

Group type: EXPERIMENTAL
Intervention: Acebutolol 400 mg once daily
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 31366980

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: 300 mg ascorbic acid
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: 600 mg ascorbic acid
Number of subjects: 93